drug · antibody
fianlimab
Phase 3updated 3mo agoby $REGN REGENERON PHARMACEUTICALS, INC.🔗 ChEMBL
Phase 3community read0 votes
Antibody drug with a maximum clinical stage of Phase 3 (across all indications), with 6 investigational indications.
targets
Lymphocyte activation gene 3 protein
all catalysts(0)
nothing on the calendar yet
Trials studying fianlimab
- phase3A Trial to Learn How the Combination of Fianlimab With Cemiplimab and Chemotherapy Works Compared With Cemiplimab and Chemotherapy for Treating Adult Patients With Advanced Non-small Cell Lung Cancer
- phase2A Study to See if Giving Fianlimab and Cemiplimab Together is Better Than Cemiplimab Alone at Treating Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
- phase1A Study to Examine the Effects of Novel Therapy Linvoseltamab in Combination With Other Cancer Treatments for Adult Participants With Multiple Myeloma That is Resistant to Current Standard of Care Treatments
- phase3A Study to Learn if a Combination of Fianlimab and Cemiplimab Versus Cemiplimab Alone is More Effective for Adult Participants With Advanced Non-Small Cell Lung Cancer (NSCLC)
- phase1A Study of Cemiplimab and Fianlimab in People With Nasopharyngeal Carcinoma
- phase2A Phase II Platform Study to Evaluate Treatment With Cemiplimab Monotherapy or Cemiplimab Plus Fianlimab or Other Novel Combinations in Patients With Colorectal Cancer With Minimal Residual Disease Following Definitive Surgery and Chemotherapy (EMPIRE)
- phase2Investigation of Ubamatamab Combination Therapy in Adult Participants With Platinum-Resistant Ovarian Cancer
- phase2Capecitabine/Oxaliplatin Chemotherapy and Cemiplimab With or Without Fianlimab or REGN7075 in Locally Advanced Rectal Cancer
News(4)
- Regeneron’s ‘aversion’ to M&A questioned as bumper Q2 builds war chestCalls for Regeneron to step up dealmaking have intensified as the company has established an $18 billion cash pile and suffered clinical trial setbacks.biospace · 12d ago
- Regeneron immunotherapy combo comes up short in melanoma trialA two-drug regimen of Regeneron’s fianlimab and Libtayo didn’t significantly outperform Keytruda in a late-stage study, a finding that surprised Wall Street analysts and wiped out billions in marke…biopharma_dive · 2mo ago
- Regeneron's Phase 3 skin cancer miss adds to mounting failures in LAG-3Regeneron Pharmaceuticals’ LAG-3 inhibitor called fianlimab has flunked a late-stage skin cancer trial, marking yet another blow for the drug class. The announcement follows a spate of recent clini…endpoints · 2mo ago
- Bristol Myers’ legacy lift, Biogen’s blue skies and Regeneron’s murky outlookInvestors are still waiting to see whether Bristol Myers and Regeneron’s pipelines will deliver, while Biogen was lifted by better-than-expected results for newer drugs like Leqembi and Skyclarys.biopharma_dive · 3mo ago
Data sources
last refreshed 33m ago
Found something off?
comments(0)
5-min edit window · permanent after that